TERAZOSIN HYDROCHLORIDE Drug Patent Profile
✉ Email this page to a colleague
When do Terazosin Hydrochloride patents expire, and when can generic versions of Terazosin Hydrochloride launch?
Terazosin Hydrochloride is a drug marketed by Apnar Pharma Lp, Bionpharma, Heritage Pharma Avet, Hikma, Jubilant Cadista, Mylan, Mylan Technologies, Ranbaxy Labs Ltd, Chartwell Rx, Ivax Sub Teva Pharms, Sandoz, and Teva. and is included in twelve NDAs.
The generic ingredient in TERAZOSIN HYDROCHLORIDE is terazosin hydrochloride. There are twenty-four drug master file entries for this compound. Twenty-one suppliers are listed for this compound. Additional details are available on the terazosin hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Terazosin Hydrochloride
A generic version of TERAZOSIN HYDROCHLORIDE was approved as terazosin hydrochloride by APNAR PHARMA LP on March 30th, 1998.
Summary for TERAZOSIN HYDROCHLORIDE
US Patents: | 0 |
Applicants: | 12 |
NDAs: | 12 |
Finished Product Suppliers / Packagers: | 21 |
Raw Ingredient (Bulk) Api Vendors: | 85 |
Clinical Trials: | 24 |
Patent Applications: | 1,659 |
Formulation / Manufacturing: | see details |
DailyMed Link: | TERAZOSIN HYDROCHLORIDE at DailyMed |
Recent Clinical Trials for TERAZOSIN HYDROCHLORIDE
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
UniversitĂ Foro Italico Roma | Phase 4 |
CNR Pisa | Phase 4 |
I.R.C.C.S. Fondazione Santa Lucia | Phase 4 |
Pharmacology for TERAZOSIN HYDROCHLORIDE
Drug Class | alpha-Adrenergic Blocker |
Mechanism of Action | Adrenergic alpha-Antagonists |